FNA News and Press, Paragon 28 Inc. From 09/11/23

Paragon 28, Inc. (NYSE: FNA), announced today they have received an Investigational Device Exemption (IDE) approval from the FDA to commence a feasibility study for configurations of the SMART Total Talus™ System used in conjunction with the Paragon 28 ® APEX 3D™ Total Ankl...

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will participate in a fireside chat at the Morgan Stanley 21 st Annual Global Healthcare Con...

2023-08-02 17:21:57 ET Paragon 28 press release ( NYSE: FNA ): Q2 Revenue of $51M (+20.0% Y/Y) beats by $0.89M . Net loss was $10.9 million for the second quarter of 2023, an increase of 13.5%, compared to a net loss of $9.6 million for the second quarter of 2022. Net ...

Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended June 30, 2023 and reaffirmed its 2023 net revenue guidance. Sec...

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO, will participate in a fireside chat at the Canaccord Genuity 43 rd Annual Growth Conferenc...

Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the second quarter 2023 after market close on Wednesday, August 2, 2023. The company’s manage...

Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of its Gorilla® Supramalleolar Osteotomy (SMO) Plating and PRESERVE™ SMO Allograft System which were developed to provide surgeons versatility in plate selection and surgical approach for supramalleolar osteotomies. The sy...

2023-05-07 07:43:01 ET Paragon 28, Inc. (FNA) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Matt Brinckman - Senior Vice President, Strategy and Investor Relations Albert DaCosta - Chairman and Chief Executive Officer Stephen Deitsc...

2023-05-04 16:58:33 ET Paragon 28 press release ( NYSE: FNA ): Q1 Net loss of $9.05M Revenue of $52M (+25.7% Y/Y). U.S. net revenue for the first quarter of 2023 was $45.0 million, representing growth of 24.9% over the first quarter of 2022. International net ...

Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended March 31, 2023 and reaffirmed its 2023 net revenue guidance. Fi...